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A method was developed for quantitative estimation of illicit psychostimulants in blood, with an emphasis on new 
psychoactive substances, based on gas chromatography nitrogen chemiluminescence detection coupled with atmospheric 
pressure chemical ionization quadrupole time-of-flight mass spectrometry (GC-NCD-APCI-QTOFMS). Quantitative 
estimation relied on the NCD’s N-equimolar response to nitrogen, using amphetamine, 3,4-
methylenedioxymethamphetamine (MDMA) and methylenedioxypyrovalerone (MDPV) as external calibrators for prim, 
sec and tert –amines, respectively. After spiking with 38 stimulants at three concentration levels, the donor blood samples 
were submitted to liquid-liquid extraction at a basic pH followed by acylation with trifluoroacetic anhydride. All but three 
psychostimulants could be analyzed with a limit of quantification (LOQ) of 0.05 mg/L. At LOQ, the between-day 
accuracy was 62.3 – 143.3% (mean 93.5%, median 88.5%) and precision 6.6 – 22.4% CV (mean 15.8%, median 16.1%). 
In addition, eleven post-mortem blood samples, containing 0.08 – 2.4 mg/L of amphetamine (n = 5), methamphetamine 
(n = 4) or MDMA (n = 4), were analyzed by the GC-NCD-APCI-QTOFMS method and the results were compared with 
an established electron ionization GC-MS method with appropriate calibration. The agreement between the two methods 
was 62.5 – 117.3%. Regarding identification, the APCI source permitted detection of the intact precursor ion, or the 
respective acylation product, for all of the measured compounds. The GC-NCD-APCI-QTOFMS method developed here 
enables instant quantitative estimation of illicit psychostimulants in blood at reasonable accuracy, without the necessity 
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Introduction 
According to the United Nations World Drug Report 2018, new psychoactive substances (NPS) continuously appear on 
the illicit drug market; a total of 803 NPS were reported during 2009–2017 (1). In Europe, approximately one additional 
NPS is reported every week to the EU Early Warning System (2). The difficulty of acquiring authentic reference standards 
sets a technical barrier to the identification and quantification of new drugs and metabolites. Furthermore, toxicological 
interpretation is difficult because reference concentrations for NPS and their metabolites in blood and urine are poorly 
understood. 
The emergence of benchtop high-resolution mass spectrometry techniques, such as quadrupole time-of-flight mass 
spectrometry (QTOFMS) and Orbitrap coupled with efficient chromatographic separation, has enabled rapid tentative 
identification of emerging NPS. In this approach, an analysis is performed without prior knowledge of the retention time 
or mass spectrum by acquiring full-spectrum data in the untargeted data-independent acquisition mode (referred to as All 
Ions MS/MS by Agilent, bbCID by Bruker, MSE by Waters, for example). Here the collision energy is alternated in such 
a manner that the precursor ion is retained at the low energy mode when a soft ionization technique, such as electrospray 
ionization (ESI) or atmospheric pressure chemical ionization (APCI), is used. Correspondingly, the high energy mode 
produces structural MS/MS information via fragmentation without any preselection of ions. Data-independent acquisition 
allows analyzing samples in advance of acquiring the reference standards, as well as the reprocessing of historic all ions 
MS/MS data, without re-extracting the stored sample. This concept has been exploited in, for example, the suspect 
screening of NPS in drug users (3-6) and wastewater analysis (7,8), as well as in the retrospective investigation of NPS 
in post-mortem blood and urine (9,10).  
Quantification by MS techniques without actual reference standards is challenging due to compound-specific ion 
responses, which can lead to gross error in the estimation of the concentration (11,12). The variation can be explained by 
differences in the sensitivity to mass spectrometric conditions, ion suppression or enhancement by the matrix compounds 
and by specific chemical properties that affect the ionization process (13). A simple and inexpensive way to escape the 
necessity of applying authentic reference standards is quantification with a universal detector, such as the flame ionization 
detector (FID), where any compound containing a known effective carbon number can be used as a reference standard 
(14). However, quantification with FID suffers from limited sensitivity and matrix interferences. The above-mentioned 
limitations can be circumvented with a nitrogen chemiluminescence detector (NCD) which has an equimolar and linear 
response to nitrogen. Furthermore, NCD offers a favorable signal-to-noise ratio as most of the drugs of abuse and NPS 
are nitrogenous compounds, while the biological matrix, especially blood, shows less nitrogen signals.  
In our earlier studies, we have demonstrated the potential of a new analytical platform in NPS bioanalysis, consisting of 
gas chromatography (GC) coupled to an NCD and APCI-QTOFMS. In this configuration, the GC flow is divided between 
the NCD for quantification, utilizing the detector's equimolar response to nitrogen, and QTOFMS for accurate mass-based 
identification (15). The GC-NCD-APCI-QTOFMS was applied to estimate the concentrations of three metabolites of the 
common stimulant NPS α-pyrrolidinovalerophenone (α-PVP) in urine samples, simulating an analysis having no authentic 
reference standards for the metabolites and using the parent drug instead for quantitative calibration (16). In the present 
study, our objective was to elaborate the analytical approach further and evaluate its performance for a broader range of 
illicit psychostimulants by investigating 38 drugs, with an emphasis on NPS, in spiked blood samples. Consequently, a 
method for quantitative estimation of these substances based on external quantitative calibration with model compounds 
was developed. Information on the method’s applicability to real samples was acquired by analyzing a series of post-
mortem case blood samples with comparison to an established quantitative electron ionization (EI) GC-MS method. 
Experimental 
Chemicals and samples  
Trifluoroacetic anhydride (TFAA) was from Sigma-Aldrich (Steinheim, Germany). Reference standards for drugs were 
from various vendors (Supplementary Table S1). Blank blood from healthy volunteers (n = 5) and donor blood from the 
Finnish Red Cross Blood Service (Helsinki, Finland) were used in the GC-NCD specificity study and in the GC-NCD 
accuracy and precision study, respectively. These blood samples from living persons contained 0.2% of potassium oxalate 
and 1% of sodium fluoride. Post-mortem femoral autopsy blank blood for the GC-NCD specificity study (n = 8) and 
femoral autopsy blood from post-mortem cases (n = 11) known to involve amphetamine, methamphetamine and 
methylenedioxymethamphetamine (MDMA) were collected by the forensic pathologists of the National Institute for 
Health and Welfare (Helsinki, Finland) into tubes containing 1% of sodium fluoride. All the samples were stored at 4ºC 
prior to analysis. 
Sample preparation  
Freshly prepared reference standards were dissolved in methanol to obtain a 1 mg/ml stock solution. The stock solution 
was diluted to 1, 5 and 25 mg/L working solutions, each containing a mixture of five to eight drugs. The blood sample (1 
ml) was transferred into a 6-ml centrifuge tube and spiked with 50 µL of the internal standard (buspirone, 5 mg/L). Blank 
blood used in the validation measurements was additionally spiked with 50 µL of the working solution to obtain a blood 
sample containing 0.05, 0.25 or 1.25 mg/L of each analyte of the drug mixture. The samples were mixed with 1 ml of 5% 
ammonium hydroxide and extracted with 0.5 ml of butyl chloride/ethyl acetate (3:1 vol/vol) in a tube rotator (40 rpm, 15 
min). Subsequently, 0.03 g NaCl was added and the tubes were closed with plastic caps prior to centrifuging (3220 g, 10 
min). The organic phase (200 µL) was transferred into another 6-ml tube and 15 µL of TFAA was added. The sample 
was mixed and heated at 50 ̊C for 15 minutes. After cooling, 700 µL of 10% NaHCO3 was added and the solution was 
mixed (3 s) and centrifuged (3220 g, 10 min). An aliquot of the organic phase (70 µL) was transferred into an autosampler 
vial for analysis.  
Analytical platform  
A 7890B Series GC System equipped with a 7693 Automatic Liquid Sampler and a split/splitless injector was coupled 
through a G3180B Two-Way Splitter with Makeup Gas (He) to an APCI 6540 UHD Accurate-Mass QTOF mass analyzer 
and a 255 Nitrogen Chemiluminescence Detector (all Agilent Technologies, Santa Clara, CA). 
GC analysis 
The injector liner was a Single taper Ultra Inert liner with glass wool (Agilent 5190-2293). Analytical column was a DB-
5MS (30 m × 0.25 mm id with 0.1 µm film) capillary column (Agilent Technologies). After the analytical column, the 
GC flow was divided between the NCD and the APCI ion source through a two-way splitter, using 0.55 m x 0.18 mm 
and 2 m x 0.18 mm uncoated deactivated fused-silica post-columns to obtain a 10:1 flow ratio, respectively. The splitter 
pressure was 15.8 psi and the flow ratio was calculated using the Effluent Splitter Calculator (with Makeup) (Agilent 
Technologies). In this concurrent detection, the NCD signal arose 0.02 minutes earlier than that of QTOFMS. The GC 
was operated in the pulsed splitless injection mode with an equilibration time of 0.75 min and 50 mL/min purge flow to 
split vent at 0.75 min. A pulse pressure of 50 psi for 0.75 min was applied prior to using initial head pressure of 24.9 psi. 
The injector port temperature was 250°C and the transfer line temperature 320°C. The injection volume was 5.0 µL. The 
oven temperature was initially held at 100°C for 0.75 min and then increased by 30°C per min to 320°C, which was held 
for 6 min. Helium was used as carrier gas at 1 mL/min in the constant flow mode. 
APCI-QTOFMS analysis 
The QTOFMS was operated in the APCI positive ionization mode, drying gas (nitrogen) flow at 5.0 L/min and gas 
temperature at 365 °C. The current of the corona discharge needle was 1000 nA and capillary voltage 1000 V. The 
fragmentor voltage was 140 V and skimmer voltage 65 V.  
Mass acquisition was performed in All Ions mode, and data were recorded over the m/z range of 50–500 with an 
acquisition rate of 5 spectra/s. Collision energy at the low energy function was 0 eV, whereas in the high energy function 
22 eV was used. External mass calibration was carried out using the APCI tuning mix (Agilent Technologies). The ion 
of m/z 257.2475 was used for internal calibration throughout the chromatographic separation. QTOFMS was operated in 
2 GHz, Extended Dynamic Range mode. 
Compound identification criteria were based on the retention time (± 0.02 min), mass accuracy (± 2 mDa), intensity 
threshold of the precursor ion (> 10 000 counts) and qualifier ions (> 1000 counts) found in the in-house GC-APCI-
QTOFMS database. A mass increment of 95.9823 Da was added to the theoretical mass of each TFAA acylation reaction 
product. All data were collected with MassHunter Data Acquisition B.04.00 software (Agilent Technologies). 
MassHunter Profinder B.06.00 software (Agilent Technologies) was used for initial data processing and compound 
identification.  
Comparison of APCI-QTOFMS responses 
Slopes for each compound were obtained from the area of a two-point calibration model (0.05 and 0.25 mg/L) measured 
on five separate days with two replicates per measurement, making in total ten measurements per compound. 
Subsequently, the ionization response was calculated by dividing the mean slope of each compound with the mean slope 
of the external calibrator (amphetamine, MDMA or MDPV). Outliers with area values beyond three standard deviations 
from the mean were removed from the data before constructing a slope.  
NCD analysis 
Pyrolysis of the analytes in the NCD was carried out at 900 °C under a hydrogen flow rate of 4 ml/min and an oxygen 
flow rate of 9.4 ml/min. Data from the NCD was collected at 50 Hz over the entire course of the analysis. OpenLab CDS 
Chemstation GC driver A.02.05.021 was used to control the GC-NCD. 
A linear regression model was constructed by measuring the external calibrators at four concentration levels (three 
replicates each), ranging from 0.05 to 2.50 mg/L, in spiked blood. To control the quantitative analysis, three external 
calibration standards were chosen as follows: amphetamine for primary amines, MDMA for secondary amines and MDPV 
for tertiary amines. The peak area of the measured compounds was corrected according to the relative nitrogen content 
prior to applying the linear regression model. 
Analysis of post-mortem blood  
Eleven post-mortem femoral blood samples, previously known to contain amphetamine, methamphetamine or MDMA, 
were analyzed by GC-NCD-APCI-QTOFMS in duplicate, and the results were compared with those from an established 
GC-EI-MS method, based on selected ion monitoring and appropriate calibration with true reference standards (17). 
Results & Discussion 
Identification by GC-APCI-QTOFMS 
For a majority of the studied compounds, derivatization was necessary to prevent adsorption of prim- and sec-amines into 
the GC system and consequently to improve their detectability in QTOFMS (18). In our established forensic casework 
GC-MS method (17), heptafluorobutyric anhydride (HFBA) is used for N-heptafluoroacylation of amines. Here we 
replaced HFBA with the less bulky and more active TFAA because the derivatization of methylphenidate with HFBA 
was unsuccessful, likely due to steric hindrance. The derivatization efficiency was checked by searching for the extracted 
ion chromatograms of the underivatized precursor ions or the intermediate derivatization products. All prim- and sec-
amines were found to be completely derivatized at all concentrations (0.05, 0.25 and 1.25 mg/L), and the expected 
precursor [M+H]+ and qualifier ions, listed in Table I, were detected for all 38 compounds. 
Table I. Characteristics of studied psychostimulant drugs 
These observations are in line with the previous studies on GC-APCI-QTOFMS, where soft ionization significantly 
promoted the detection of precursor ion, thus enabling accurate mass-based tentative identification (19-21). 
Accuracy and precision in GC-NCD 
Recognition of chromatographic peaks at NCD was based on their parallel detection by APCI-QTOFMS. Table II shows 
the accuracy and precision of GC-NCD quantification for the 38 psychostimulants in spiked healthy donor blood, based 
on five separate experiments at three concentration levels (0.05, 0.25 and 1.25 mg/L). The LOQ was assigned 0.05 mg/L, 
and the mean between-day accuracy and precision at LOQ was 93.5% (62.3-143.4%) and 15.8% CV (6.6-22.4%), 
respectively. The values were even better at the higher concentrations. Figure 1 visualizes the detector’s response at the 
three concentration levels.  
Table II. Between-day accuracy and precision for quantitative estimation of drugs by GC-NCD using equimolar response 
to nitrogen and external calibration with three model compounds 
Figure 1. Overlaid GC-NCD chromatograms from blood samples spiked at 0.05, 0.25, and 1.25 mg/L of 4-
fluoroamphetamine (4-FA), ethylcathinone, 4-methylthioamphetamine (4-MTA), α-pyrrolidinovalerophenone (α-PVP), 
camfetamine, ethylphenidate and 2-desoxypipradrol (2-DPMP) 
These results are not in every case consistent with the principles of bioanalytical method validation stating that the mean 
accuracy and precision should be within ±15% and less than 15% CV (at LOQ within ±20% and less than 20% CV), 
respectively (22). However, our findings suggest that the present method for quantitative estimation of psychostimulants 
in blood by GC-NCD approximates the true concentration with such an accuracy (±50%) that toxicologically meaningful 
interpretations can be made. 
As for comparison, to illustrate the problems associated with MS-based quantification in the absence of the actual 
reference standards, we measured the same 38 compounds under the same experimental conditions by the APCI-
QTOFMS. Applying external calibration with amphetamine, MDMA and MDPV, similarly to the GC-NCD experiment, 
resulted in a fairly consistent slope with some drugs, but with others a large difference in slopes was found, up to 2.86-
fold (286% error) (Table III). Moreover, the MS response is largely unpredictable as opposed to NCD that shows a more 
uniform performance. 
Table III. Relative ion response in GC-APCI-QTOFMS using external quantitative calibration with three model 
compounds 
Specificity of GC-NCD  
The specificity of GC-NCD analysis was established with blank blood samples from post-mortem cases (n = 8) and from 
healthy volunteers (n = 5). The common interfering peaks from the matrix are listed in Figure 2. The same peaks were 
found in samples from both post-mortem and living persons in varying intensities. Dibutylone (6.51 min) and 
methylphenidate (6.77 min) partially co-eluted with an interfering matrix component and MBDB (6.48 min) was 
completely covered by a matrix peak, which made integration difficult especially at the lowest concentration level. In 
addition, the common exogenous compound caffeine (6.57 min) was a potential interference for camfetamine (6.62 min). 
The caffeine signal ([M+H]+ = m/z 195.0882) was detected in all blank blood samples by APCI-QTOFMS, but only three 
samples contained a detectable peak in GC-NCD.  
Figure 2. Overlaid GC-NCD chromatograms from blood samples of a healthy volunteer (above) and a post-mortem case 
(below) with commonly observed matrix peaks listed according to their retention time values 
Method comparison between GC-NCD and GC-EI-MS with post-mortem cases 
Eleven post-mortem blood samples, previously known to contain amphetamine (n = 5), methamphetamine (n = 4) and 
MDMA (n = 4) as analyzed by an established GC-EI-MS method (17), were subsequently re-analyzed by GC-NCD-
APCI-QTOFMS. Table IV shows that the agreement of quantitative results between the methods was 62.5-117.3%, which 
can be considered sufficient reproducibility in post-mortem toxicology, taking into account the fundamental differences 
between the methods in terms of detection and quantitative calibration.  
Table IV. Comparison of quantitative results for selected drugs between GC-NCD and an established GC-EI-MS 
method in post-mortem blood 
Advantages and limitations of GC-NCD-APCI-QTOFMS 
GC-NCD-APCI-QTOFMS constitutes an efficient integrated platform for the identification and quantitative estimation 
of nitrogen-containing drugs, the analyst having no immediate need of the respective authentic reference standards. Our 
new findings strengthen the previously published results on the benefits of the GC-APCI source, enabling tentative 
identification by soft ionization (19-21). However, unequivocal identification can be accepted only after confirmation 
analysis based on the actual reference standards afterwards. As for quantification, GC-NCD enables better 
chromatographic resolution and sufficient sensitivity compared with its LC counterpart (23,24), making the technique 
amenable to bioanalysis. The N-equimolar response of NCD is stable with little variation, contrary to MS techniques for 
which unpredictable and large differences in response may exist between compounds. 
However, there are some limitations concerning the use of GC-NCD-APCI-QTOFMS in bioanalysis. Firstly, appropriate 
derivatization of prim- and sec-amino as well as hydroxyl groups is essential. This in turn necessitates that the spectral 
libraries and mass databases should include the corresponding derivatives. Secondly, quantitative estimation by GC-NCD 
without reference standards requires calibration by suitable model compounds to compensate for all other stages of 
analysis but the N-equimolar detection. Inappropriate sample preparation and/or calibration may result in a systematic 
bias while precision may still remain acceptable. Our results show that the choice of calibrators for the psychostimulants 
was largely appropriate, but this may not be obvious with other types of drugs and metabolites. Thirdly, the specificity 
and sensitivity of the NCD is not comparable to MS. To improve specificity, common interferences in the NCD 
chromatogram should be recognized using a similar matrix prior to the actual analysis and the required methodological 
modifications made. The sensitivity of the NCD analysis was considered adequate for the psychostimulants in blood, but 
there is certainly room for improvement if low-dose drugs are involved. Lastly, quantification by NCD is limited to 
nitrogen-containing drugs. It has been shown that the equimolar principle was truly universal regardless of the position 
or number of nitrogen atoms but decreased nitrogen signal was observed in such cases where nitrogen atoms were adjacent 
to each other [25].    
Conclusions 
This is the first study applying the recently introduced GC-NCD-APCI-QTOFMS platform to the accurate mass-based 
tentative identification and quantitative estimation of drugs in human blood, simulating an analysis having no authentic 
reference standards available for the drugs and using model compounds instead for external quantitative calibration. Based 
on three external calibrators, we have successfully quantified 35 out of 38 illicit psychostimulants with an accuracy 
somewhat outside of what is encountered with methods that are calibrated using authentic reference standards but at a 
level that meets the requirements of meaningful toxicological interpretation. However, subsequent confirmation analysis 
using reference standards is necessary for professionally valid reporting. We conclude that GC-NCD-APCI-QTOFMS is 
among the most viable approaches for the instant estimation of stimulant NPS concentrations in blood, having very few 
challengers within analytical toxicology.  
Compliance with ethical standards 
The collection and use of the blood samples obtained from living persons was undertaken with the understanding and 
written consent of each subject. The analysis of drugs from the autopsy specimens was performed according to the request 
of judicial authorities, and the study was based on an appropriate permission.  
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Tertiary amines Slope relative to MDPV Fold change
MDPV 1,00 1,00
4-F-aPVP 0,98 1,02
Dibutylone 1,03 1,03
a-PVP 0,79 1,27
PCP 0,36 2,78
Naphyrone 0,35 2,86
